Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Language: English
- 183 Pages
- Published: April 2012
This product is currently not available for purchase.
This model provides detailed sales and volume forecast data for the inflammatory bowel disease market. Including Crohn's disease and ulcerative colitis market sizing, within the context of total brand sales across the seven major markets.
Key reasons to purchase this title
- Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
- Understand IBD market trends and assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
- Access a case study assessing the likelihood of ulcerative colitis approval for Humira and Simponi with three alternative scenario forecasts